Second Sight Medical Products (EYES) Shares are Up 6.99%

Second Sight Medical Products (EYES) : Traders are bullish on Second Sight Medical Products (EYES) as it has outperformed the S&P 500 by a wide margin of 2.88% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.81%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.99% in the last 1 week, and is up 2.33% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 6.15% and the 50-Day Moving Average is 2.86%.The 200 Day SMA reached 20.11%


Second Sight Medical Products (NASDAQ:EYES): After opening at $3.3, the stock dipped to an intraday low of $3.2501 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $3.6 and the buying power remained strong till the end. The stock closed at $3.52 for the day, a gain of 7.98% for the day session. The total traded volume was 663,688. The stocks close on the previous trading day was $3.52.

Second Sight Medical Products, Inc. is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Companys product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant, a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU), and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada, Turkey, and at one medical center in Saudi Arabia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.